Nenad Lujic1, Jelena Sopta2, Relja Kovacevic2, Vladan Stevanovic3, Radoslav Davidovic4. 1. Institute for Orthopedic Surgery "Banjica", School of Medicine, University of Belgrade, M. Avramovica St. 28, 11000, Belgrade, Serbia. 2. Institute for Pathology, Medical Faculty, School of Medicine, University Belgrade, Dr Subotica 1, 11000, Belgrade, Serbia. 3. Institute for Orthopedic Surgery "Banjica", School of Medicine, University of Belgrade, M. Avramovica St. 28, 11000, Belgrade, Serbia. drvladanstevanovic@gmail.com. 4. Institute of Nuclear Sciences "Vinča", University of Belgrade, Mike Alasa 12-14, 11000, Belgrade, Serbia.
Abstract
PURPOSE: To determine various clinical, radiographic, and pathological parameters which may indicate an increased risk of Giant cell tumour of bone (GCTB) recurrence after surgical therapy. METHODS: The study included a total of 164 GCTB samples; 118 (72 %) primary tumours, and 46 (28 %) recurrences; which were analyzed on immunohistochemistry for expression of Ki67, p53, cyclin D1, and β-catenin. RESULTS: Among 13 analyzed clinical, radiological, and histological variables, which presented possible predictive factors for the incidence of GCTB relapse, univariate logistic regression (ULR) extract three highly statistically significant parameters: 1) lesion localization, 2) nuclear p53 expression in mononuclear cells, and 3) nuclear cyclin D1 expression in giant multinuclear cells. The multivariate logistic regression (MLR), revealing that p53 expression in mononuclear cells was the most significant predictive factor (HR = 6,181 p < 0,001), the positivity of which indicated six times higher probability for recurrence in GCTB. The expression of cyclin D1 in giant cells, containing less than 15 nuclei, was also statistically significant (HR = 8,398, p = 0,038) for predicting the recurrence, and demonstrated eight times more frequent recurrence in positive tumours. CONCLUSIONS: This study confirmed independent predicting factors for GCTB reccurence: p53 expression in mononuclear tumour cells and cyclin D1 expression in giant multinuclear cells. Results are new addition to generally known parameters, such as: localization of lesion, number of surgical interventions, clear destruction of cortex with the presence of extracompartmental lesion, and histological criteria for malignancy and can help in further research and treatment of GCTB.
PURPOSE: To determine various clinical, radiographic, and pathological parameters which may indicate an increased risk of Giant cell tumour of bone (GCTB) recurrence after surgical therapy. METHODS: The study included a total of 164 GCTB samples; 118 (72 %) primary tumours, and 46 (28 %) recurrences; which were analyzed on immunohistochemistry for expression of Ki67, p53, cyclin D1, and β-catenin. RESULTS: Among 13 analyzed clinical, radiological, and histological variables, which presented possible predictive factors for the incidence of GCTB relapse, univariate logistic regression (ULR) extract three highly statistically significant parameters: 1) lesion localization, 2) nuclear p53 expression in mononuclear cells, and 3) nuclear cyclin D1 expression in giant multinuclear cells. The multivariate logistic regression (MLR), revealing that p53 expression in mononuclear cells was the most significant predictive factor (HR = 6,181 p < 0,001), the positivity of which indicated six times higher probability for recurrence in GCTB. The expression of cyclin D1 in giant cells, containing less than 15 nuclei, was also statistically significant (HR = 8,398, p = 0,038) for predicting the recurrence, and demonstrated eight times more frequent recurrence in positive tumours. CONCLUSIONS: This study confirmed independent predicting factors for GCTB reccurence: p53 expression in mononuclear tumour cells and cyclin D1 expression in giant multinuclear cells. Results are new addition to generally known parameters, such as: localization of lesion, number of surgical interventions, clear destruction of cortex with the presence of extracompartmental lesion, and histological criteria for malignancy and can help in further research and treatment of GCTB.
Entities:
Keywords:
Cyclin D1; Giant cell tumour of bone; Recurrence; p53
Authors: Robert E Turcotte; Jay S Wunder; Marc H Isler; Robert S Bell; Norman Schachar; Bassam A Masri; Guy Moreau; Aileen M Davis Journal: Clin Orthop Relat Res Date: 2002-04 Impact factor: 4.176
Authors: Corey J Chakarun; Deborah M Forrester; Christopher J Gottsegen; Dakshesh B Patel; Eric A White; George R Matcuk Journal: Radiographics Date: 2013 Jan-Feb Impact factor: 5.333
Authors: Maurice Balke; Laura Schremper; Carsten Gebert; Helmut Ahrens; Arne Streitbuerger; Gabriele Koehler; Jendrik Hardes; Georg Gosheger Journal: J Cancer Res Clin Oncol Date: 2008-03-06 Impact factor: 4.553
Authors: Mate E Maros; Peter Balla; Tamas Micsik; Zoltan Sapi; Miklos Szendroi; Holger Wenz; Christoph Groden; Ramses G Forsyth; Piero Picci; Tibor Krenacs Journal: Pathol Oncol Res Date: 2021-05-03 Impact factor: 3.201